Friday 16 October 2026
Export ADCT’s income statement to Excel — free account
ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
1.41
0.08
−5.37%
Follow ADCT
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | — | 1 | 3 | 5 |
Altman Z-Score |
— | — | — | — | (0.50) | (2.23) | (5.55) | (6.61) | (6.67) |
P/S ratio |
0.00 | 0.00 | 0.00 | — | 43.21 | 1.34 | 1.99 | 2.73 | 5.51 |
Altman Z″-Score (non-manufacturers) |
— | (2.14) | (7.16) | — | (2.55) | (4.04) | (10.76) | (13.96) | (14.62) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(47.62) | (47.62) | (47.62) | — | (25.15) | (5.23) | (4.37) | (8.85) | (14.41) |
Beneish M-Score |
— | — | 2.76 | — | — | 1.36 | (5.19) | (2.67) | (2.09) |
P/B ratio |
13.75 | 13.75 | 13.75 | — | 9.33 | 3.53 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
13.75 | 13.75 | 13.75 | — | 10.17 | 4.31 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | — | 33.88 | 0.36 | (0.19) | 0.99 | 3.72 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 |
EV/Operating CF |
(9.22) | (9.22) | (9.22) | — | (5.21) | (0.55) | 0.11 | (0.57) | (2.14) |
EV/FCF |
(9.19) | (9.19) | (9.19) | — | (5.06) | (0.54) | 0.11 | (0.56) | (2.15) |
Quick Ratio |
12.88 | 6.22 | 5.89 | 10.93 | 6.72 | 4.87 | 4.49 | 3.37 | 4.14 |
Current Ratio |
12.91 | 6.36 | 6.15 | 11.14 | 7.10 | 5.31 | 4.97 | 3.62 | 4.37 |
Net Debt/EBITDA |
2.88 | 1.11 | 0.94 | 1.51 | 1.29 | 1.69 | 1.02 | 1.08 | 1.22 |
Debt/Assets |
0.00% | 0.00% | 3.65% | 21.73% | 21.31% | 24.89% | 31.77% | 35.29% | 35.73% |
Debt/Equity |
0.00 | 0.00 | 0.05 | 0.33 | 0.79 | 1.54 | (0.76) | (0.56) | (0.62) |
Asset Turnover |
0.01 | 0.02 | 0.02 | 0.00 | 0.06 | 0.38 | 0.16 | 0.21 | 0.25 |
Operating CF/Net income |
0.83 | 0.99 | 1.04 | 0.69 | 1.01 | 0.88 | 0.49 | 0.78 | 0.99 |
Capex/Depreciation |
0.00 | (3.34) | (1.30) | (1.28) | (2.42) | (1.01) | (0.98) | (0.26) | 0.21 |
Interest Coverage |
0.00 | (44.10) | (765.38) | (44.51) | (14.27) | (3.36) | (3.58) | (2.60) | (2.35) |
| (47.87%) | (65.58%) | (98.13%) | (110.28%) | (91.72%) | (127.99%) | 697.85% | 89.97% | 73.43% | |
| (42.54%) | (163.52%) | (80.82%) | (75.62%) | (40.65%) | (28.34%) | (56.77%) | (46.65%) | (44.22%) | |
ROIC |
0.00% | 0.00% | (11,733.39%) | (1,729.42%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(36.56%) | (101.51%) | (111.96%) | (59.83%) | (50.52%) | (44.09%) | (87.53%) | (73.12%) | (60.39%) |
Average Days of Receivables |
390.10 | 61.47 | 310.09 | 0.00 | 325.19 | 126.89 | 132.14 | 104.68 | 130.63 |
Research and Development Expense of Revenue |
4,732.45% | 10,378.33% | 4,595.60% | 0.00% | 465.85% | 88.83% | 182.76% | 154.77% | 127.84% |
Selling, General and Administrative Expense of Revenue |
432.95% | 769.12% | 606.92% | 0.00% | 401.69% | 68.36% | 152.23% | 121.28% | 98.25% |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.06 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 41.14% | 47.74% | 0.00% | 178.32% | 23.50% | 19.40% | 9.27% | 8.49% |
Graham Net Nets |
0.08 | 0.08 | 0.08 | — | 0.05 | 0.08 | (1.21) | (1.21) | (0.45) |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 10.94 | 8.80 | 6.28 |
Earnings Yield |
(2.17%) | (2.17%) | (2.17%) | — | (14.85%) | (55.99%) | (173.37%) | (82.91%) | (33.99%) |
Free Cash Flow Yield |
(10.08%) | (10.08%) | (10.08%) | — | (15.50%) | (50.15%) | (88.33%) | (64.53%) | (31.40%) |
Revenue per Share |
581.61 | 0.02 | 0.05 | 0.00 | 0.44 | 2.69 | 0.85 | 0.73 | 0.64 |
Operating CF per Share |
(24,175.81) | (2.60) | (2.47) | (2.58) | (3.04) | (1.77) | (1.45) | (1.27) | (1.11) |
Capex per Share |
0.00 | (0.05) | (0.04) | (0.04) | (0.08) | (0.03) | (0.04) | (0.01) | 0.00 |
Free Cash Flow per Share |
(24,175.81) | (2.66) | (2.51) | (2.62) | (3.12) | (1.80) | (1.49) | (1.28) | (1.11) |
Cash per Share |
84,758.71 | 2.98 | 2.34 | 6.71 | 6.08 | 4.18 | 3.41 | 2.58 | 2.06 |
Shareholders Equity per Share |
80,376.13 | 2.71 | 2.26 | 5.13 | 2.16 | 1.02 | (1.81) | (2.09) | (1.46) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
80,376.13 | 2.71 | 2.26 | 5.13 | 2.16 | 1.02 | (1.81) | (2.09) | (1.46) |
Free Cash Flow |
(74.94) | (123.83) | (123.73) | (171.54) | (239.75) | (140.72) | (121.90) | (124.70) | (140.78) |
Working Capital |
244.63 | 119.73 | 102.66 | 410.01 | 451.25 | 353.04 | 268.62 | 210.79 | 236.17 |
Capital Expenditures |
(3.16) | (2.47) | (2.15) | (2.81) | (6.38) | (2.41) | (3.22) | (0.87) | 0.40 |
Net Current Asset Value |
242.39 | 117.77 | 96.08 | 272.26 | 73.30 | 23.57 | (166.74) | (233.37) | (202.65) |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 2.17 | 0.92 | 0.00 | 0.19 | 0.01 | 0.05 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.30 | 0.48 | 1.20 | 1.34 | 0.65 | 0.71 | 0.58 | 0.65 | 0.00 |
Cash ROIC |
(14.64%) | (46.72%) | (53.39%) | (19.35%) | (31.37%) | (26.65%) | (50.15%) | (77.04%) | (73.72%) |
Accounts Receivable Turnover |
0.99 | 1.08 | 2.15 | 0.00 | 2.06 | 4.07 | 1.42 | 3.11 | 3.29 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.46 | 0.16 | 0.27 | 0.18 | 0.35 | 0.43 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.28 | 0.18 | 0.65 | 1.80 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 977.10 | 3,165.25 | 1,365.68 | 2,247.01 | 1,106.17 | 577.59 |
Days of Inventory on Hand |
— | — | — | 0.00 | 2,914.24 | 1,334.94 | 2,334.76 | 138.11 | 263.39 |
Average Receivables |
1.82 | 1.06 | 1.09 | 2.34 | 16.45 | 51.59 | 49.08 | 22.75 | 24.72 |
Average Payables |
7.18 | 7.18 | 5.04 | 4.30 | 8.68 | 12.22 | 13.96 | 16.80 | 13.60 |
Average Inventory |
— | — | — | — | — | 11.60 | 14.13 | 9.21 | 3.22 |
Average Assets |
211.25 | 75.28 | 144.12 | 325.69 | 565.83 | 554.42 | 422.82 | 338.38 | 322.57 |
Average Common Equity |
187.70 | 187.70 | 118.70 | 223.33 | 250.80 | 122.77 | (34.40) | (175.45) | (194.24) |
Columns are period end dates